Pexelizumab (Alexion, MA), a monoclonal antibody against C5 is under phase 3 clinical trials for Acute myocardial infarction and CABG (Mathew et al., 2004; Kulkarni and Afshar-Kharghan, 2008). Here, C5 is linked to myocardial infarction.